{"filing":{"accession_number":"0001104659-26-095905","cik":"0001374339","ticker":"PMN","company_name":"ProMIS Neurosciences Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"pmn-20260813x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813x8k.htm"},"events":[{"id":27573,"run_id":25141,"accession_number":"0001104659-26-095905","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ProMIS Neurosciences issued a press release on August 13, 2026, reporting financial results for the quarter ended June 30, 2026, including a net loss of $11.7 million, cash position of $53.4 million, and cash runway through 2027. The filing explicitly states under Item 2.02 that the Company \"issued a press release...reporting its financial condition and financial results as of and for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1 and incorporated by reference. The exhibit contains condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026 and 2025, which are standard quarterly financial results disclosures.","company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29158,"accession_number":"0001104659-26-095905","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProMIS Neurosciences issued a press release on August 13, 2026, reporting financial results for the quarter ended June 30, 2026, including a net loss of $11.7 million, cash position of $53.4 million, and cash runway through 2027. The filing explicitly states under Item 2.02 that the Company \"issued a press release...reporting its financial condition and financial results as of and for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1 and incorporated by reference. The exhibit contains condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026 and 2025, which are standard quarterly financial results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:00:38.659250+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29158,"accession_number":"0001104659-26-095905","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ProMIS Neurosciences issued a press release on August 13, 2026, reporting financial results for the quarter ended June 30, 2026, including a net loss of $11.7 million, cash position of $53.4 million, and cash runway through 2027. The filing explicitly states under Item 2.02 that the Company \"issued a press release...reporting its financial condition and financial results as of and for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1 and incorporated by reference. The exhibit contains condensed consolidated balance sheets and statements of operations for the periods ended June 30, 2026 and 2025, which are standard quarterly financial results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:00:38.659250+00:00","company_name":"ProMIS Neurosciences Inc.","ticker":"PMN","filing_date":"2026-08-13"}]}